Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Discover key highlights in healthcare stocks, including UnitedHealth's surge after a Buffett stake, Eli Lilly lawsuits, Trump pharma tariffs & Bayer's ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

A restful night’s sleep is vital to a healthy lifestyle but an Indiana physician said most Americans are not getting enough ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Zepbound approved for treating moderate to severe obstructive sleep apnea in adults with obesity, showing improvement in ...

There’s a new kind of nosy parker on the rise in the United States, a person who thinks it’s fine to blurt out “Are you on ...